RecruitingPhase 1NCT06483048
MUC1-Activated T Cells for the Treatment of Relapsed and Resistant Ovarian Cancer
Studying Malignant mixed Müllerian tumor of the ovary
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Mayo Clinic
- Principal Investigator
- Brenda J. Ernst, M.D.Mayo Clinic
- Intervention
- Autologous MUC1-activated T-cells(biological)
- Enrollment
- 12 enrolled
- Eligibility
- 18 years · FEMALE
- Timeline
- 2024 – 2028
Study locations (1)
- Mayo Clinic in Arizona, Scottsdale, Arizona, United States
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT06483048 on ClinicalTrials.govOther trials for Malignant mixed Müllerian tumor of the ovary
Additional recruiting or active studies for the same condition.
See all trials for Malignant mixed Müllerian tumor of the ovary →